Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Just a warning.

<< Previous

Bullboard Posts

Next >>

Comment by Rarbar99on Nov 10, 2021 9:43am

185 Views

Post# 34109329

RE:RE:Just a warning.

Hate to say I told you so, but yeah, I told you so

Rarbar99 wrote:

Rarbar99 wrote: This isn't going to be a quick bleed, the whales of this company would lose a lot more money if they dumped it all at one time. It's going to be slow, gradual bleed, and this will eventually go back to the 0.80 range and possibly below. Mark my words, this will be my final post here, good luck.